In a Friday interview with CNBC’s Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson explained how his company uses new AI technology to develop drugs.

Nvidia is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships with Amgen and Recursion Pharmaceuticals.

Recursion announces the close of a $121 million Series C financing to advance its machine learning-enabled approach to drug discovery and development.

Recursion's AI-Powered Drug Revolution Recursion is a clinical-stage TechBio company that is fundamentally built upon the principles of artificial intelligence and machine learning.

Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further ...